He unexpectedly becomes a father at the start of his life, and the mother of his child is a national

Third, from a technical perspective, after breaking through $75, BHTX showed obvious signs of weakness in its upward movement, forming a small high-level platform around $78, but the trading volume shrank day by day.

Although the stock closed slightly higher today, it failed to break through $79 several times during the day, and several small but decisive sell orders appeared at the end of the day.

This is a typical pattern of high-level stagnation and exhaustion of momentum.

Fourth, and most importantly, Chen Hao, through special information channels, judged that the FDA's approval attitude towards this groundbreaking, high-risk gene therapy might be more cautious than the market expected.

Especially when faced with academic questions and concerns about safety data, the FDA may require the company to provide more data or even postpone the approval decision.

Any rumors of "delays" or "need for more data" would be devastating for a stock whose share price has already priced in all the optimistic expectations.

Taking all factors into account, Chen Hao concluded that BHTX's stock price was severely overvalued and contained a huge bubble.

In the next two or three trading days, there is a high probability of a sharp drop due to any adverse news, with the decline likely to reach 25% or even more.

This is the target for shorting.

Without hesitation, Chen Hao dialed Li Qingshan's number again.

He knew that Li Qingshan might have just experienced a close call and was still in shock, but the opportunity was fleeting.

When the call connected, Li Qingshan's voice still carried a hint of lingering fear and exhaustion: "Haozi? What's wrong? Is there something else?"

"Qingshan, I've got my eye on another stock, and I'm planning to short it," Chen Hao said bluntly.

"Short selling? Which one?" Li Qingshan immediately became alert.

"BioHeal Therapeutics, code BHTX".

The sound of rapid typing came from the other end of the phone, followed by Li Qingshan's gasp:

"BHTX? Haozi, are you sure? This stock has been a huge winner lately! It's almost doubled in value!"

The market is waiting for its new drug approval! Shorting this kind of stock... is too risky!

"If positive news comes out and the stock price soars again, short sellers will be wiped out! Are you...analyzing wrong?"

Li Qingshan's reaction was exactly what Chen Hao expected.

Any rational investor, upon seeing a stock in a strong upward trend with clear positive expectations, would not immediately consider shorting it.

"Qingshan, my analysis was correct." Chen Hao's voice was calm and firm. "The rise of this stock has come to an end."

Its price is entirely based on the assumption that 'BH-101' will be successfully approved and that it will be able to monopolize the market and make a lot of money.

But this assumption is fragile.

He quickly and concisely conveyed his analysis to Li Qingshan: academic doubts, competitor dynamics, technological fatigue, and the FDA's potentially more cautious assessment than expected.

"The market either didn't see these risks or selectively ignored them."

However, with the stock price currently at a high level, any slight disturbance could trigger a panic sell-off.

"I think the probability of a decline is far greater than the probability of an increase," Chen Hao concluded.

Li Qingshan listened silently, his fingers rapidly scanning the information Chen Hao had mentioned on his computer.

He saw the summary of the reader's letter, the news about the competitors, and the chart of BHTX showing high volume and stagnant price.

To be fair, Chen Hao's analysis was logically sound, and the risks he pointed out did indeed exist.

However... shorting a hot star stock requires more than just analysis; it also requires immense courage and the determination to go against the market trend.

He recalled Chen Hao's several incredibly accurate moves in the past, from Star Shine Entertainment to NeuroTech. Each one seemed risky, but in the end, Chen Hao was always right.

My own analysis and judgment seem to be inferior to Chen Hao's.

After a moment's internal struggle, Li Qingshan gritted his teeth and said, "Fine! Haozi, I trust you! You say short selling, then short selling! This time I'll stick with you!"

"Okay," Chen Hao replied, then raised a more crucial question, "This time, could you help me get an even higher leverage? 10 times, or more?"

"Ten times?!" Li Qingshan's voice rose eight octaves.

"Haozi, are you crazy? Short selling is already risky, and you're using 10x leverage? If you're even slightly wrong, you'll..."

"I know the risks," Chen Hao interrupted him.

"But the opportunities are also great. Fortune favors the bold."

It doesn't matter if the interest rate is high, as long as you make the right judgment, you can earn far more than the interest.

"Qingshan, think of a way."

Li Qingshan scratched his head on the other end of the phone.

Tenfold leverage is practically the limit for individual investors through legitimate channels, with extremely strict vetting processes and shockingly high interest rates.

But Chen Hao's successes these times gave him an almost blind confidence in his childhood friend's abilities.

Maybe... it really can work?

"...I'll try." Li Qingshan finally managed to utter those three words with difficulty.

"I know a friend who works in private equity. Their channels are a bit more unconventional, so there might be opportunities there."

But the interest rates can be very high, and the conditions are very demanding.

Wait for my message, I'll contact you right away.

"Okay, as soon as possible. The market waits for no one."

After Chen Hao finished speaking, he hung up the phone, leaned back on the sofa, closed his eyes to rest, and waited for Li Qingshan's reply.

The waiting time seemed exceptionally long.

Chen Hao could imagine how frantically Li Qingshan was making phone calls, begging for help, and explaining things over there.

He wasn't sure if it would work out, but he had to try.

Leverage is a tool to amplify returns, and this opportunity is worth taking greater risks for him.

About ten minutes later, the phone finally rang again.

Chen Hao immediately answered the call: "How is it?"

Li Qingshan's voice on the other end of the phone was a little hoarse, but it conveyed excitement and relief:

"It's done! Haozi, 10x leverage! But it's through my friend's private equity channel, using off-exchange margin financing, with an interest rate of... 36% per annum!"

Furthermore, they require you to have sufficient margin, and if the risk level is high, they have the right to liquidate the position early.

"Can you accept these conditions?"

An annualized interest rate of 36% is astonishingly high, almost the limit within the legal range.

But Chen Hao accepted almost without hesitation.

If handled properly, the interest cost can be negligible over a few days.

How to operate? "

"You transfer your money to their designated regulated account, they provide you with leverage, and the trading instructions still go through our channels, but the risk control is monitored by them."

"The account is open. I'll send you the information and agreement right away." Li Qingshan spoke very quickly.